Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERLOPET: FDG-/FLT-PET for Early Prediction of Erlotinib Response in NSCLC
NCT00568841Phase 2Unknown
- Sponsor
- Lung Cancer Group Cologne
- Start
- Oct 2007
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Lung Cancer Group Cologne. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00568841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00568841.